iQue® SARS-CoV-2 (IgG, IgM and IgA) Kit

The outbreak of SARS-CoV-2 continues to persist due to constant mutation and evasion. Protection against the virus is dependent upon development of a humoral immune response, meaning the need is ongoing for accurate assessment of quantity and duration of antibody response (particularly those targeting the SARS-CoV-2 spike protein receptor binding domain). Serological testing to quantitate the three major isotypes (IgG, IgM and IgA) of antibodies specific for SARS-CoV-2 Spike RBD can be used to facilitate characterization and monitor the duration of the antibody response in both COVID-19 patients and vaccinated individuals, detect asymptomatic infections and survey past infection prevalence in a population. With the iQue^® SARS-CoV-2 (IgG, IgM and IgA) Kit, detection is fast and reliable.

Innovation for Smarter Research

While traditional enzyme-linked immunosorbent assay (ELISA), lateral flow immunoassay and flow cytometry can be used to detect anti-SARS-CoV-2 Spike RBD IgG, IgM or IgA antibodies, these methods have limitations:

• Provide only qualitative results
• Labor-intensive, may not support high-throughput applications
• Large amounts of reagents required
• Do not allow multiplexing analysis of IgG, IgM and IgA antibodies

The iQue^® SARS-CoV-2 (IgG, IgM and IgA) kit provides a rapid, robust and sensitive serological assay for the measurement of IgG, IgM and IgA anti-SARS-CoV-2 Spike RBD antibodies in a single well of a 96 or 384-well plate with antibody detection levels in the pg/mL range.

Maximized Productivity

The multiplexed assay enables high-throughput analysis of the three major isotypes (IgG, IgM and IgA) of antibodies specific for SARS-CoV-2 Spike RBD in a single well for comprehensive analysis of immune response.

Save Precious Samples

Conserve laboratory samples by using a streamlined workflow that requires only a single 10 µL sample diluted at least 100-fold. Get robust and accurate data without exhausting resources like reagents.